GlassScriptPhysician profile
Pedro R Rodriguez
NPI 1184617961
$10,896.65
in general payments reported to CMS, 2019-2025
59 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,219 · 2020: $757 · 2021: $1,158 · 2022: $1,005 · 2023: $1,513 · 2024: $1,608 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,754 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,753.52 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $754.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $731.06 | 2019-2025 | Breztri |
| Abbvie INC. | $729.50 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Boston Scientific Corporation | $687.45 | 2019-2025 | Watchman Flx, General - Brady |
| Lilly USA, LLC | $685.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Medtronic, INC. | $482.48 | 2022-2025 | Synchromedii, Interstim, Venaseal |
| Abbott Laboratories | $354.81 | 2019-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Pfizer INC. | $337.48 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $313.77 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $300.31 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Teva Pharmaceuticals USA, INC. | $297.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.86 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Madrigal Pharmaceuticals | $270.80 | 2025 | Rezdiffra |
| Eisai INC. | $261.84 | 2021-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.